An Official Website of the United States Government
Company Information:
Name:
ETUBICS CORPORATION
Address:
9715 FREMONT AVE N
SEATTLE, WA 98103-3140
SEATTLE, WA 98103-3140
Located in HUBZone:
No
Woman-Owned:
No
Minority-Owned:
No
URL:
N/A
Phone:
N/A
Award Totals:
Award List:
Improved HIV-Adenoviral Vector Vaccine for Re-immunization
Award Year / Program / Phase:
2006 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Richard B. Gayle
Award Amount:
$621,380.00
Abstract:
DESCRIPTION (provided by applicant): The objective of this project is to develop an adenoviral vector vaccine against HIV that is effective in stimulating cell-mediated immunity in animals previously immune to adenovirus The HIV vaccine will be used to protect against infection and to treat the… More
Development of a Novel CEA Expressing Adenovirus for Treatment
Award Year / Program / Phase:
2008 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Award Amount:
$112,995.00
Abstract:
DESCRIPTION (provided by applicant): The objective of this project is to continue developing an adenoviral vector vaccine against CEA that is effective in stimulating cell-mediated immunity in animals previously immune to adenovirus. The Ad-CEA vaccine en
dpoint is to treat patients with CEA… More
Development of a Novel Her2/neu Expressing Adenovirus for Treatment
Award Year / Program / Phase:
2009 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Frank R. Jones
Award Amount:
$123,567.00
Abstract:
DESCRIPTION (provided by applicant): The objective of this project is to continue developing an adenoviral serotype 5 (Ad5) vector vaccine against Ad5[E1-, E2b]-Her2/neu that is effective in stimulating cell-mediated immunity (CMI) in animals previously i
mmune to Ad5. The Ad5[E1-, E2b-]- Her2/neu… More
Development of an Ad5 [E1-, E2b-] HIV-1 vaccine for use in Ad5 Immunized Vaccinee
Award Year / Program / Phase:
2009 / SBIR / Phase II
Agency:
HHS
Principal Investigator:
Frank R. Jones
Award Amount:
$3,353,817.00
Abstract:
DESCRIPTION (provided by applicant): Current generation Adenovirus (Ad) vector vaccines deleted at the E1 or the E1, E3 regions have resulted in experimental potential to immunize against a variety of infectious diseases such as HIV. These Ad vectors permi
t the delivery of genes, which express… More
Development of a Novel CEA Expressing Ad5 [E1-, E2b-] Vector for Treatment
Award Year / Program / Phase:
2009 / SBIR / Phase II
Agency:
HHS
Principal Investigator:
Frank R. Jones
Award Amount:
$2,470,285.00
Abstract:
DESCRIPTION (provided by applicant): The objective of this project is to continue to develop an adenoviral vector vaccine against CEA that is effective in stimulating cell-mediated immune responses in subjects previously immune to Adenovirus. The Ad-CEA v
accine endpoint is to treat patients with… More
Therapeutic Vaccine for HIV/HPV-associated Oropharyngeal and Tonsillar Malignanci
Award Year / Program / Phase:
2011 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Frank R. Jones – 206-838-5110
Award Amount:
$163,405.00
Abstract:
DESCRIPTION (provided by applicant): The objective of this project is to develop a therapeutic strategy for H V-associated malignancy based on the role of HPV in the pathogenesis. HPV related cancers express the E6/E7 oncoproteins of HPV that are ideal targets for immune inducing vaccines. We will… More
TAS::75 0849::TAS TOPIC 255 CGMP MANUFACTURE OF A NOVEL HER2/NEU EXPRESSING ADENOVIRUS FOR TREATMENT
Award Year / Program / Phase:
2011 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Joseph Balint – 206-838-5110
Award Amount:
$199,988.00
Abstract:
This Phase I, SBIR contract is for the development of a new vaccine targeting HER2/neu expressing breast cancers. The vaccine induces both cell-mediated and humoral immunity and the company is planning a first-in-man Phase I/Phase II clinical trial. It isanticipated that this new biotherapeutic… More
TAS::75 0849 - TOPIC 255 PHASE II, CGMP MANUFACTURE OF A NOVEL CEA EXPRESSING AD5 VIRUS
Award Year / Program / Phase:
2011 / SBIR / Phase II
Agency:
HHS
Principal Investigator:
Frank Jones – 206-838-5110
Award Amount:
$1,499,001.00
Abstract:
Etubics Corporation is clinically testing a new vaccine targeting carcinoembryonic antigen (CEA) expressing cancers in a Phase I/II clinical trials under FDA IND14325. Many cancers express CEA, including colon, breast and pancreatic cancers. It is anticipated that this new biotherapeutic product… More